39 completed, 13 recruiting, 13 terminated, 9 active not recruiting. 86 Phase 2, 12 Phase 1, 5 Phase 3.
Follow merphos: new trials by email Literature Review of merphos trials Research Report on merphos
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Addition of a New Anti-Cancer Drug, Glofitamab to Usual Chemotherapy for Burkitt and Double Hit Lymphoma Biospecimen Collection, Bone Marrow Biopsy, Carboplatin - Recurrent Burkitt Lymphoma, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements | Phase 2 / Phase 3 | Not yet recruiting | National Cancer Institute (NCI) | 271 | 2026-10-30 | 2026-08-19 |
| Testing Blinatumomab With or Without Revumenib in Patients With B-cell Acute Lymphoblastic Leukemia With a Genetic Change Requiring More Treatment Biospecimen Collection, Blinatumomab, Bone Marrow Aspiration - Acute Leukemia of Ambiguous Lineage, B Acute Lymphoblastic Leukemia | Phase 2 | Not yet recruiting | SWOG Cancer Research Network | 90 | 2026-10-14 | 2026-10-13 |
| Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL) Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration - Stage II T Lymphoblastic Leukemia/Lymphoma, Stage III T Lymphoblastic Leukemia/Lymphoma | Phase 2 / Phase 3 | Not yet recruiting | Children's Oncology Group | 1708 | 2026-08-28 | 2026-07-30 |
| Ruxolitinib Before, During and After Hematopoietic Cell Transplant in Older Patients With Myelofibrosis and Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes Ruxolitinib, Allogeneic Hematopoietic Stem Cell Transplantation, Busulfan - Myelodysplastic/Myeloproliferative Neoplasm, Primary Myelofibrosis | Phase 2 | Recruiting | Fred Hutchinson Cancer Center | 50 | 2026-02-04 | 2026-10-19 |
| Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma Asparaginase Erwinia chrysanthemi, Biospecimen Collection, Bone Marrow Aspiration - B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative, Lymphoblastic Lymphoma | Phase 2 | Recruiting | City of Hope Medical Center | 53 | 2025-10-10 | 2026-10-13 |
| Methotrexate, Erlotinib, and Celecoxib for the Treatment of Recurrent/Metastatic Head and Neck Cancer in a Rural Midwest United States Population Celecoxib, Erlotinib Hydrochloride, Imaging Procedure - Metastatic Oral Cavity Carcinoma, Recurrent Oral Cavity Carcinoma | Phase 2 | Recruiting | Mayo Clinic | 25 | 2025-08-07 | 2026-10-01 |
| Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia Asparaginase Erwinia chrysanthemi, Biospecimen Collection, Blinatumomab - Acute Leukemia of Ambiguous Lineage, B Acute Lymphoblastic Leukemia | Phase 2 | Recruiting | National Cancer Institute (NCI) | 153 | 2025-06-05 | 2026-10-27 |
| Intrathecal Cytarabine, Methotrexate, and Hydrocortisone for the Prevention of High-Grade Chimeric Antigen Receptor T-Cell-Associated Neurotoxicity Syndrome Biospecimen Collection, Cytarabine, Lumbar Puncture - Hematopoietic and Lymphatic System Neoplasm | Phase 2 | Recruiting | OHSU Knight Cancer Institute | 26 | 2025-06-04 | 2026-06-26 |
| A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL) Biospecimen Collection, Blinatumomab, Bone Marrow Biopsy - B Acute Lymphoblastic Leukemia | Phase 2 | Recruiting | National Cancer Institute (NCI) | 222 | 2025-05-30 | 2026-10-27 |
| Adding Targeted Drugs to Usual Chemotherapy for Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LBL) Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - T Acute Lymphoblastic Leukemia, T Lymphoblastic Lymphoma | Phase 2 | Withdrawn | National Cancer Institute (NCI) | 2024-08-09 | 2024-05-17 | |
| Ruxolitinib With Tacrolimus and Methotrexate for the Prevention of Graft Versus Host Disease in Pediatric and Young Adult Patients Undergoing Allogeneic Hematopoietic Cell Transplant for Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome Biospecimen Collection, Chest Computed Tomography, Echocardiography - Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia | Phase 2 | Recruiting | City of Hope Medical Center | 40 | 2024-08-01 | 2026-10-14 |
| A Study of Revumenib in Combination With Chemotherapy for Patients Diagnosed With Relapsed or Refractory Leukemia Biospecimen Collection, Bone Marrow Aspiration, Calaspargase Pegol - Recurrent Acute Leukemia of Ambiguous Lineage, Recurrent Acute Lymphoblastic Leukemia | Phase 2 | Active not recruiting | Children's Oncology Group | 78 | 2024-01-08 | 2026-08-25 |
| A Study of the Drug IMGN632 in Children With Leukemia That Has Come Back After Treatment or is Difficult to Treat Anti-CD123 ADC IMGN632, Bone Marrow Aspiration and Biopsy, Cytarabine - Recurrent Acute Myeloid Leukemia, Recurrent B Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | Withdrawn | Children's Oncology Group | 2023-08-01 | 2023-09-01 | |
| A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosarcoma Bone Scan, Cabozantinib S-malate, Cisplatin - High Grade Osteosarcoma, Localized Osteosarcoma | Phase 2 / Phase 3 | Suspended | National Cancer Institute (NCI) | 1122 | 2023-03-03 | 2026-10-27 |
| Tagraxofusp and Low-Intensity Chemotherapy for the Treatment of CD123 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma Cyclophosphamide, Cytarabine, Dexamethasone - Recurrent Adult Lymphoblastic Lymphoma, Recurrent B Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | Terminated | M.D. Anderson Cancer Center | 4 | 2022-02-17 | 2025-08-11 |
| Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer Biopsy Procedure, Biospecimen Collection, Cisplatin - Renal Pelvis and Ureter Urothelial Carcinoma | Phase 2 / Phase 3 | Recruiting | National Cancer Institute (NCI) | 131 | 2021-11-12 | 2026-11-05 |
| Comparing ATG or Post-Transplant Cyclophosphamide to Calcineurin Inhibitor-Methotrexate as GVHD Prophylaxis After Myeloablative Unrelated Donor Peripheral Blood Stem Cell Transplantation Anti-Thymocyte Globulin, Busulfan, Cyclophosphamide - Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Phase 2 | Withdrawn | Fred Hutchinson Cancer Center | 2021-06-01 | 2021-06-30 | |
| DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia DS-1594b, Azacitidine, Cyclophosphamide - Hematopoietic and Lymphoid Cell Neoplasm, Recurrent Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | Terminated | M.D. Anderson Cancer Center | 17 | 2021-03-25 | 2025-05-23 |
| Peritransplant Ruxolitinib for Patients With Primary and Secondary Myelofibrosis Allogeneic Hematopoietic Stem Cell Transplantation, Busulfan, Cyclophosphamide - Primary Myelofibrosis, Secondary Myelofibrosis | Phase 2 | Active not recruiting | Fred Hutchinson Cancer Center | 53 | 2020-12-18 | 2026-04-14 |
| A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL) 3-Dimensional Conformal Radiation Therapy, Asparaginase Erwinia chrysanthemi, Biospecimen Collection - Down Syndrome, Recurrent B Acute Lymphoblastic Leukemia | Phase 2 | Recruiting | National Cancer Institute (NCI) | 461 | 2020-12-17 | 2026-09-01 |
Showing 20 of 86. Sign in to see all of them.
Precursor Cell Lymphoblastic Leukemia-Lymphoma (28) · Burkitt Lymphoma (26) · Leukemia, Myeloid, Acute (13) · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (13) · Leukemia, Myeloid, Accelerated Phase (11) · Blast Crisis (10) · Lymphoma, Mantle-Cell (9) · Congenital Abnormalities (7) · Hodgkin Disease (7) · Leukemia, Biphenotypic, Acute (7) · Leukemia, Myelomonocytic, Chronic (7) · Lymphoma, Large B-Cell, Diffuse (7) · Lymphoma, Non-Hodgkin (7) · Hematologic Neoplasms (6) · Leukemia, Lymphocytic, Chronic, B-Cell (6)
National Cancer Institute (NCI) (22) · M.D. Anderson Cancer Center (21) · Fred Hutchinson Cancer Center (12) · Children's Oncology Group (7) · University of Washington (4) · City of Hope Medical Center (2) · Eastern Cooperative Oncology Group (2) · Mayo Clinic (2) · Northwestern University (2) · OHSU Knight Cancer Institute (2) · Roswell Park Cancer Institute (2) · Case Comprehensive Cancer Center (1) · ECOG-ACRIN Cancer Research Group (1) · Fox Chase Cancer Center (1) · SWOG Cancer Research Network (1)
United States (80) · Australia (9) · Canada (9) · Puerto Rico (9) · New Zealand (2)
Elias Jabbour (8) · Farhad Ravandi-Kashani (2) · Ibrahim Aldoss (2) · Issa Khouri (2) · Marie Bleakley (2) · Rachel B. Salit (2) · Anjali S Advani (1) · Anne Angiolillo (1) · Aref Al-Kali, M.D. (1) · Barbara Pro, MD (1) · Boglarka Gyurkocza (1) · Chitra Hosing (1) · David Ebb (1) · Edward A Neuwelt (1)
PMID 35622074, PMID 41671463, PMID 35007144, PMID 20466853, PMID 23233571, PMID 24077846, PMID 24146219, PMID 24821881, PMID 25964296, PMID 26432046, PMID 28419486, PMID 29618479, PMID 29785709, PMID 29812996, PMID 30117142, PMID 30501869, PMID 30957229, PMID 31212080, PMID 31702432, PMID 31969338, PMID 32154021, PMID 32589978, PMID 33191168, PMID 33242441, PMID 33684925, PMID 34138471, PMID 34162404, PMID 34492682, PMID 34797699, PMID 35007127, PMID 35074072, PMID 35157306, PMID 36279879, PMID 36322825, PMID 36402146, PMID 36534942, PMID 36600670, PMID 36841758, PMID 38207208, PMID 38237077, PMID 38867582, PMID 39028925, PMID 40369607
U10CA180886 (12), U10CA098543 (9), P30CA015704 (5), P30CA016672 (5), U10CA180888 (4), P01HL036444 (3), U10CA021115 (3), U10CA031946 (3), U10CA180821 (3), P01CA018029 (2), P30CA033572 (2), P30CA060553 (2), R01HL121568 (2), U10CA180820 (2), K23CA154532 (1)